Search

Author/Creator Dudoit, Yasmine

1. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. (25th October 2020)

Authors:
Palich, Romain; Allavena, Clotilde; Peytavin, Gilles; Soulie, Cathia; Tubiana, Roland; Weiss, Laurence; Montoya Ferrer, Ana; Duvivier, Claudine; Bouchaud, Olivier; Bottero, Julie; Durand, Aurore; Lê, Minh-Patrick; Marcelin, Anne-Geneviève; Dudoit, Yasmine; Assoumou, Lambert; Katlama, Christine
Journal:
Journal of antimicrobial chemotherapy
Issue:
Volume 76:Number 2(2021)
Page Start:
477
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. (13th March 2016)

Authors:
Calin, Ruxandra; Hamimi, Chiraz; Lambert-Niclot, Sidonie; Carcelain, Guislaine; Bellet, Jonathan; Assoumou, Lambert; Tubiana, Roland; Calvez, Vincent; Dudoit, Yasmine; Costagliola, Dominique; Autran, Brigitte; Katlama, Christine
Journal:
AIDS
Issue:
Volume 30:Number 5(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. (13th March 2016)

Authors:
Calin, Ruxandra; Hamimi, Chiraz; Lambert-Niclot, Sidonie; Carcelain, Guislaine; Bellet, Jonathan; Assoumou, Lambert; Tubiana, Roland; Calvez, Vincent; Dudoit, Yasmine; Costagliola, Dominique; Autran, Brigitte; Katlama, Christine
Journal:
AIDS
Issue:
Volume 30:Number 5(2016)
Page Start:
761
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search